After "7 days and 5 boards", Qianjiang Yongan Pharmaceutical refutes the rumors of "taurine price skyrocketing" | Quick reading of the announcement.

① Qianjiang Yongan Pharmaceutical has again reached its price limit today, with a Turnover Ratio of 31%, recording 5 price limits within 7 days; ② The company stated that the rumors circulating online recently about "taurine prices skyrocketing several times" are false; ③ After turning a profit in 2024, Qianjiang Yongan Pharmaceutical fell back into loss again in the first quarter of this year.

cls.cnApr 29 11:01 ET

Nanjing King-Friend Biochemical Pharmaceutical turned a profit last year, but its net profit in Q1 this year halved year-on-year | Interpretations

① After clearing the inventory risk of heparin Active Pharmaceutical Ingredient, Nanjing King-Friend Biochemical Pharmaceutical successfully turned losses into profits last year; ② The impact of centralized procurement mainly reduced the gross margin of key products, with pressure continuing into this year, and the first quarter's Net income nearly halved; ③ Tariffs from the USA have not yet had a significant impact on the company's Business, but the company will focus on developing markets outside the USA.

cls.cnApr 28 12:00 ET

Jiangsu Hengrui Pharmaceuticals: Authorized revenue becomes the "accelerator" for performance.

Personnel, products, and research and development are gradually becoming Global.

wallstreetcnApr 24 07:29 ET

The upfront payment for the new ADC drug has boosted revenue, Jiangsu Hengrui Pharmaceuticals' Q1 revenue increased by 20.14% year-on-year, and net income increased by 36.9% | Earnings Reports insights.

In Q1, Jiangsu Hengrui Pharmaceuticals' revenue increased by 20.14% year-on-year, net income attributable to the parent company increased by 36.9%, and net income after deductions increased by 29.35% year-on-year. The significant increase in net income was primarily due to the company receiving a $75 million upfront payment for external licensing.

wallstreetcnApr 24 06:03 ET

Fumetinib drives performance growth, Shanghai Allist Pharmaceuticals Co., Ltd. expects net profit to increase by over 120% year-on-year in 2024.

① During the reporting period, Shanghai Allist Pharmaceuticals Co., Ltd. achieved revenue of 3.558 billion yuan, a year-on-year increase of 76.29%; net income attributable to shareholders was 1.43 billion yuan, up 121.97% year-on-year, and net income excluding extraordinary items was 1.361 billion yuan, an increase of 124.51% year-on-year; ② The net cash flow reached 1.566 billion yuan, a growth of 132.12% compared to 0.675 billion yuan in the same period last year. Ample funds are beneficial for expanding R&D investment.

cls.cnApr 24 00:28 ET

Limit up during the day and a warning at night? JiangSu WuZhong Pharmaceutical Development's annual report may receive an audit report with an inability to express an opinion | Quick read of the announcement.

① Due to various reasons such as overdue accounts receivable and receivables overdue in the trade business, JiangSu WuZhong Pharmaceutical Development does not rule out the possibility of receiving an audit report expressing an inability to issue an opinion in the 2024 report. ② In addition to being investigated for violations of information disclosure and multiple Bearish factors, JiangSu WuZhong is currently in a precarious situation.

cls.cnApr 23 11:59 ET